OakChart

Fractyl Health Inc

GUTSHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.8812+0.0705 (8.70%)
2026-11-11 22:42 CET
Market cap
10.75 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-105.65 USD m
Free cash flow, TTM
-82.44 USD m
EPS diluted, TTM
-13.12
P/E
-
Compare

Price

GUTS against its 20, 50 and 200-day averages
2050200beatmissearnings
5.0010.007.5M15.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GUTSclose 0.8820-day 1.1950-day 4.19200-day 6.950.88

97.0% under the 52-week high of 29.34 on 12 Dec 2025. 52-week low 0.80 on 11 Nov 2026. Last 15 sessions, 56.3% high to low

Volume 0.30× normal · the line is the 50-bar volume average

Profile

GUTS
52-week range, 0% of the way up
0.8129.34

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Employees100
IPOFeb 02, 2024
Beta2.91
ATR, 14d0.26
Rel volume0.30
Short float5.19%
Insider own15.01%
Inst own39.05%

Snapshot

6 groups

Valuation

Index-
Market Cap11.68M
Enterprise Value25.28M
Income-105.65M
Sales0.00M
Book/sh-0.13
Cash/sh3.56
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees100
IPOFeb 02, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C0.25
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.15
Current Ratio3.15
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-13.12
EPS next Y-5.79
EPS next Q-1.50
EPS this Y81.17%
EPS next Y-37.72%
EPS next 5Y42.51%
EPS past 3/5Y-11.62% -16.69%
Sales past 3/5Y- -
EPS Y/Y TTM46.66%
Sales Y/Y TTM-100.00%
EPS Q/Q71.69%
Sales Q/Q-
EarningsNov 12 AMC
EPS/Sales Surpr.-18.52% -

Ownership

Insider Own15.01%
Insider Trans13.45%
Inst Own39.05%
Inst Trans-3.37%
ROA-146.75%
ROE-778.33%
ROIC-196.04%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-26.00%
SMA50-78.99%
SMA200-87.31%
Trades-

Technical

Shs Outstand13.22M
Shs Float11.27M
Short Float5.19%
Short Ratio1.24
Short Interest0.59M
52W High29.34 -97.00%
52W Low0.81 8.76%
Volatility10.96% 13.96%
ATR (14)0.26
RSI (14)20.86
Beta2.91
Rel Volume0.30
Avg Volume472.38K
Volume139,751

Performance

Perf Week-9.39%
Perf Month-78.11%
Perf Quarter-88.91%
Perf Half Y-92.26%
Perf YTD-96.66%
Perf Year-93.32%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price41.20
Prev Close0.81
Price0.88
Change %8.70%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Jan 30, 2026DowngradeMMorgan StanleyOverweight → Equal-Weight$2+127.0%
Sep 15, 2025InitiatedHH.C. WainwrightBuy$9+921.3%
Aug 28, 2025InitiatedLLadenburg ThalmannBuy$3.60+308.5%
Feb 28, 2024InitiatedEEvercore ISIOutperform
Feb 27, 2024InitiatedMMorgan StanleyOverweight$18+1,942.7%
Feb 27, 2024InitiatedBBofA SecuritiesBuy$26+2,850.5%

Peers

Mkt cap
TickerCompanyMkt cap
BMEABiomea Fusion Inc44.28M
AARDAardvark Therapeutics Inc34.79M
ALTAltimmune Inc375.41M
SKYESkye Bioscience Inc4.06M
GPCRStructure Therapeutics Inc ADR1.49B
MBXMBX Biosciences Inc2.87B
VKTXViking Therapeutics Inc3.63B
LXRXLexicon Pharmaceuticals Inc832.59M
RYTMRhythm Pharmaceuticals Inc7.78B
BIOABioAge Labs Inc269.78M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
BRADLEY WILLIAMDirectorSep 14 '26Buy0.6264,51639,903149,138Sep 16 04:05 PM
Royan AjayDirectorJun 12 '26Buy0.8523,00019,59640,901Jun 15 06:06 PM
BRADLEY WILLIAMDirectorJun 10 '26Buy0.7368,49350,32984,622Jun 11 05:04 PM
Sheffield IanDirectorJun 10 '26Buy0.7335,00025,52935,000Jun 11 05:00 PM
Rajagopalan HarithChief Executive OfficerJun 10 '26Buy0.7325,00018,252540,557Jun 11 04:59 PM
Smith Weber LaraChief Financial OfficerJun 08 '26Buy0.6920,00013,70820,000Jun 09 06:55 PM
Rajagopalan HarithChief Executive OfficerDec 04 '25Buy1.9210,41619,999501,745Dec 08 07:05 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Fractyl Health's Q3 Report Becomes A Test Of Cash And Credibility After An 88% Collapse (Earnings Whispers)
  • Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026 (GlobeNewswire)
  • Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization (GlobeNewswire)
  • Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance (GlobeNewswire) +11.40%
  • Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance (GlobeNewswire)
  • Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans (InvestorsHub) -62.74%
  • Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation (GlobeNewswire)
  • Robbins LLP is Investigating Allegations that Fractyl Health, Inc. Misled Investors Regarding the Viability and Efficacy of its Revita DMR System (Newsfile) +10.40%
  • GUTS Stockholders Have Rights - If you Lost Money Investing in Fractyl Health, Inc. Contact Robbins LLP for Information About Recovering Your Losses (Business Wire) +5.03%
  • Fractyl Health to Participate in Upcoming September Investor Conferences (GlobeNewswire) -6.60%
  • Did You Lose Money Investing in Fractyl Health, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against GUTS (Newsfile)
  • Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day (InvestorsHub)
  • Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita, a Procedural Therapy for Post-GLP-1 Weight Maintenance (GlobeNewswire)
  • Fractyl Health Inc (GUTS) (Q2 2026) Earnings Call Highlights: Pivotal Data on Track and ... (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--1.502--0.006
2026Q22026-08-10-1.920-1.620-1.9200.000.006
2026Q12026-05-120.720-1.9200.6980.000.005
2025Q42026-03-24-3.750-2.160-3.4210.000.005
2025Q32025-11-12-8.430-3.787-8.4640.000.005
2025Q22025-08-12-6.686-4.320-6.8240.000.003
2025Q12025-05-13-5.700-5.720-5.8290.000.003
2024Q42025-03-03-6.240-5.220-6.1460.000.012
2024Q32024-11-12-5.160-6.000-5.7960.01-1
2024Q22024-08-14-3.360-5.520-4.3160.04-1
2024Q12024-05-130.000-3.600-1.2670.03-1
2023Q42024-04-01-134.16-7.800-62.5140.01-1
2026Q4---1.219--0.006
2027Q1---0.885--0.002
2027Q2---0.830--0.002
2027Q3---0.810--0.752

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-543.48-214.62-253.270.120.13
2024FY-19.440-19.260-17.3350.090.05
2025FY-22.102-19.296-22.3200.000.00
2026FY--4.203--0.00
2027FY--5.789--19.15
2028FY--4.240--78.92
2029FY--1.090--201.82
2030FY-3.550--350.66

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-113000.000.000.00
2026Q3S2026-08-103000.000.000.00
2026Q3S2026-06-303000.000.000.00
2026Q3S2026-05-132000.000.000.00
2026Q3S2026-03-252000.000.000.00
2026Q3S2025-11-192000.000.000.00
2026Q3S2025-11-131000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00

Estimate history

EPS, annual-9.696-10.31-13.415-16.04-253.273-17.335-22.309-13.1191
Period2019202020212022202320242025TTM
EPS, quarterly-4.316-5.796-6.146-5.829-6.824-8.464-3.4210.698-1.932
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000.120.09300
Period2019202020212022202320242025TTM
Sales, quarterly0.0430.0140.003000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual3.9673.9673.9673.9670.3774.06312.78113.221
Period2019202020212022202320242025MRQ
Shares, quarterly3.9934.0074.0634.0774.1611.01812.78113.22113.221
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.090.120.000.000.000.00
Cost of Goods Sold Incl. D&A1.131.130.730.360.450.680.770.89
Gross Profit-1.13-1.13-0.63-0.24-0.45-0.68-0.77-0.89
Selling, General and Administrative Excl. Other84.7795.6992.9050.5948.9336.2528.1929.03
Research and Development63.3674.5470.4738.0434.3526.4322.4320.89
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-85.89-96.82-93.53-50.84-49.38-36.93-28.96-29.92
Interest Expense-----1.441.500.64
Unusual Expense21.5745.62-20.7427.49-2.140.360.010.04
Net Income Before Taxes-105.65-140.95-68.69-77.09-46.45-38.73-30.48-30.59
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-105.65-140.95-68.69-77.09-46.45-38.73-30.48-30.59
Net Income From Continuing Operations-105.65-140.95-68.69-77.09-46.45-38.73-30.48-30.59
Net Income-105.65-140.95-70.43-94.27-63.63-53.22-40.90-38.47
EPS (Recurring)-6.85-17.25-20.91-201.57-16.42-13.35-10.31-9.69
EPS (Basic, Before Extraordinaries)-13.12-22.31-17.34-253.27-16.04-13.41-10.31-9.70
EPS (Diluted)-13.12-22.31-17.34-253.27-16.04-13.41-10.31-9.70
EBITDA-84.77-95.69-92.85-50.55-48.93-36.25-28.19-29.03
Non-Operating Income (Expense)1.811.494.101.240.79-0.01-0.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.526.6814.434.303.142.091.632.52
Price To Sales Ratio--1,079.96-----
Gross Margin---681.72-202.50----
Operating Margin---100,570.97-42,363.33----
Net Margin---75,732.26-78,559.17----
Shares Outstanding13.2212.784.060.383.973.973.973.97
Market Capitalization10.7510.75100.4497.62----

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.01
Cost of Goods Sold Incl. D&A0.280.280.280.290.270.290.220.22
Gross Profit-0.28-0.28-0.28-0.29-0.27-0.29-0.22-0.20
Selling, General and Administrative Excl. Other18.8220.5423.0022.4025.8124.4724.9923.59
Research and Development13.8115.6016.4917.4621.1519.4320.2819.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-19.10-20.82-23.28-22.69-26.08-24.76-25.21-23.79
Unusual Expense6.87-29.4521.0823.072.02-0.540.480.32
Net Income Before Taxes-25.549.22-43.73-45.60-27.89-23.73-24.97-23.17
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-25.549.22-43.73-45.60-27.89-23.73-24.97-23.17
Net Income From Continuing Operations-25.549.22-43.73-45.60-27.89-23.73-24.97-23.17
Net Income-25.549.22-43.73-45.60-27.89-23.73-24.97-23.17
EPS (Recurring)-1.57-0.86-2.27-5.47-6.48-5.92-6.06-5.74
EPS (Basic, Before Extraordinaries)-1.930.70-3.42-8.46-6.82-5.83-6.15-5.80
EPS (Diluted)-1.930.70-3.42-8.46-6.82-5.83-6.15-5.80
EBITDA-18.82-20.54-23.00-22.40-25.81-24.47-24.99-23.59
Non-Operating Income (Expense)0.420.590.630.160.210.480.720.94
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.502.531.851.641.781.412.902.52
Price To Sales Ratio---34,266.074,673.50969.171,079.961,251.28
Gross Margin-------7,333.33-1,442.86
Operating Margin-------840,333.33-169,957.14
Net Margin-------832,333.33-165,521.43
Shares Outstanding13.2213.2212.7811.024.164.084.064.01
Market Capitalization10.7572.63337.42210.2280.8758.22100.44121.67

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments81.5467.4633.5249.2795.4729.115.79
Short Term Receivables0.000.000.020.000.000.000.00
Inventories0.000.070.070.000.000.000.00
Other Current Assets6.044.232.032.360.921.770.99
Total Current Assets87.5871.7635.6551.6396.3930.886.78
Net Property, Plant & Equipment29.2331.3930.771.651.341.362.12
Total Investments and Advances4.254.254.254.250.000.000.00
Intangible Assets--0.830.860.000.000.00
Other Assets0.340.674.702.564.822.520.03
Total Assets121.40108.0876.2160.96102.5534.768.93
Short Term Debt Incl. Current Port. of LT Debt5.104.962.731.2516.677.170.00
Accounts Payable1.573.240.550.000.000.000.00
Other Current Liabilities11.6511.587.906.066.983.753.41
Total Current Liabilities18.3319.7711.197.3123.6510.923.41
Long Term Debt56.5457.54370.99305.56287.66195.60148.01
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities37.072.3319.100.410.560.961.51
Total Liabilities111.9479.65401.27313.27311.87207.48152.93
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity9.4628.42-325.06-252.32-209.32-172.72-144.00
Total Shareholders Equity9.4628.42-325.06-252.32-209.32-172.72-144.00
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity9.4628.42-325.06-252.32-209.32-172.72-144.00
Total Liabilities & Stockholders Equity121.40108.0876.2160.96102.5534.768.93
Book Value Per Share0.747.00-863.17-63.60-52.76-43.54-36.30
Tangible Book Value Per Share0.747.00-865.39-63.82-52.76-43.54-36.30
Full-Time Employees100107102947361-
Price to Book Ratio-6.443.531.94----
Return on Assets-122.85-74.55-112.40-56.82-56.42-139.52-
Return on Equity-744.17------
Return on Invested Capital-213.57-79.91-167.85-87.26-49.45-133.21-761.37
Quick Ratio4.783.633.187.064.072.831.99
Current Ratio4.783.633.197.064.072.831.99

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-105.65-140.95-68.69-77.09-46.45-38.73-30.48-30.59
Depreciation1.131.130.680.290.450.680.770.89
Other Funds (Non Cash)27.7349.89-7.1032.991.002.892.142.79
Funds from Operations-76.79-89.93-75.11-43.81-45.00-35.17-27.57-26.91
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-5.63-0.409.590.99-1.241.71-3.51-0.82
Cash from Operating Activities-82.43-90.33-65.52-42.82-46.24-33.46-31.07-27.73
Capital Expenditures-0.01-0.56-1.76-0.36-0.06-0.05-0.00-0.10
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.56-1.76-0.36-0.06-0.05-0.00-0.10
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock107.77105.42101.41-0.510.3299.8954.400.22
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock107.77105.42101.41-0.510.3299.8954.400.22
Proceedsfrom Stock Options83.9885.40100.84-0.560.0099.8554.370.00
Issuance or Reduction of Debt, Net-0.49-0.46-0.1927.954.03-0.01-0.0114.95
Change in Long Term Debt-0.49-0.46-0.1927.954.03-0.01-0.0114.95
Issuance of Long Term Debt0.000.000.0028.0320.070.000.0014.95
Reduction of Long Term Debt-0.49-0.46-0.19-0.08-16.05-0.01-0.01-0.01
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities107.29104.96101.2327.444.3599.8854.3915.16
Net Change in Cash24.8514.0833.94-15.74-41.9566.3723.32-12.66
Free Cash Flow-82.44-90.89-67.29-43.18-46.30-33.51-31.07-27.83
Preferred Dividends (Cash Flow)-0.00------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments47.1463.1781.5477.6622.2942.11
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.462.756.042.054.404.94
Total Current Assets49.6065.9287.5879.7026.6947.05
Net Property, Plant & Equipment27.8228.5329.2329.9230.6131.17
Total Investments and Advances4.254.254.254.254.254.25
Other Assets0.300.680.340.390.460.57
Total Assets81.9899.39121.40114.2762.0183.04
Short Term Debt Incl. Current Port. of LT Debt5.185.145.105.075.034.99
Accounts Payable1.011.651.571.263.911.48
Other Current Liabilities9.558.6211.6512.3512.8912.33
Total Current Liabilities15.7415.4118.3318.6821.8318.80
Long Term Debt55.5655.6856.5457.1256.6956.43
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities12.356.9237.0741.651.701.43
Total Liabilities83.6478.01111.94117.4580.2276.67
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-1.6721.389.46-3.18-18.216.38
Total Shareholders Equity-1.6721.389.46-3.18-18.216.38
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-1.6721.389.46-3.18-18.216.38
Total Liabilities & Stockholders Equity81.9899.39121.40114.2762.0183.04
Book Value Per Share-0.131.620.74-0.29-4.381.56
Tangible Book Value Per Share-0.131.620.74-0.29-4.381.56
Full-Time Employees--100101103-
Price to Book Ratio-6.443.4035.68-66.15-4.449.13
Return on Assets-146.75-118.41-122.85-101.33-95.73-72.28
Return on Equity--778.33-744.17-518.40-379.75-196.81
Return on Invested Capital-47.3911.96-66.25-84.55-72.48-37.79
Quick Ratio3.154.284.784.271.222.50
Current Ratio3.154.284.784.271.222.50

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-25.549.22-43.73-45.60-27.89-23.73
Depreciation0.280.280.280.290.270.29
Other Funds (Non Cash)8.79-27.4822.3324.103.200.27
Funds from Operations-16.47-17.99-21.12-21.22-24.42-23.18
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.57-4.49-0.22-1.503.22-1.90
Cash from Operating Activities-15.90-22.48-21.34-22.71-21.20-25.08
Capital Expenditures0.000.00-0.00-0.01-0.10-0.45
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.00-0.01-0.10-0.45
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.004.2325.3478.201.590.28
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.004.2325.3478.201.590.28
Proceedsfrom Stock Options-4.064.2326.9356.881.590.00
Issuance or Reduction of Debt, Net-0.13-0.12-0.12-0.12-0.11-0.11
Change in Long Term Debt-0.13-0.12-0.12-0.12-0.11-0.11
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.13-0.12-0.12-0.12-0.11-0.11
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.134.1125.2278.091.480.17
Net Change in Cash-16.03-18.373.8855.37-19.82-25.36
Free Cash Flow-15.90-22.48-21.34-22.72-21.30-25.53

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 93.00K
United States2024: 93.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.19%0.6M11.3M458.48K
2026-10-152.35%0.3M11.3M148.14K
2026-09-301.58%0.2M11.3M138.27K
2026-09-151.98%0.2M11.3M136.87K
2026-08-311.63%0.2M11.3M134.77K
2026-08-142.03%0.2M10.9M137.84K
2026-07-312.41%0.3M10.8M164.97K
2026-07-151.94%0.2M10.8M165.79K
2026-06-301.78%0.2M10.8M156.96K
2026-06-151.79%0.2M10.8M174.69K
2026-05-291.86%0.2M10.8M184.94K
2026-05-152.38%0.3M10.8M202.42K
2026-04-302.30%0.3M10.9M248.29K
2026-04-152.93%0.3M11.0M449.66K
2026-03-314.64%0.5M10.7M473.81K
2026-03-135.25%0.5M9.2M479.38K
2026-02-2711.86%1.1M9.2M514.85K
2026-02-1312.78%1.2M9.2M508.90K
2026-01-3013.13%1.2M9.5M445.59K
2026-01-1510.70%1.0M9.5M239.47K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-063Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-068-KCurrent report2026-11-02SEC
2026-10-228-KCurrent report2026-10-21SEC
2026-10-168-KCurrent report2026-10-16SEC
2026-10-13SCHEDULE 13GSEC
2026-10-018-KCurrent report2026-09-30SEC
2026-09-248-KCurrent report2026-09-24SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-118-KCurrent report2026-09-10SEC
2026-08-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-24SEC
2026-08-14PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-24SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-158-KCurrent report2026-07-15SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-118-KCurrent report2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-048-KCurrent report2026-06-04SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-13SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0939.90K100
2026-080000
2026-070000
2026-06127.41K500
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1220.00K100
2025-110000

Institutional holders

Manager% owned
Nantahala Capital Management, LLC14.23%
Catalio Capital Management, LP3.89%
VANGUARD CAPITAL MANAGEMENT LLC3.84%
BANK OF AMERICA CORP /DE/3.80%
Pale Fire Capital SE3.15%
General Catalyst Group Management, LLC3.08%
Deer Management Co. LLC3.01%
MAVERICK CAPITAL LTD2.51%
M28 Capital Management LP1.17%
BlackRock, Inc.1.14%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.91%
VANGUARD EXTENDED MARKET INDEX FUND0.79%
Fidelity Extended Market Index Fund0.37%
Fidelity Total Market Index Fund0.13%
Fidelity Series Total Market Index Fund0.11%
Goldman Sachs Absolute Return Tracker Fund0.07%
Fidelity Nasdaq Composite Index Fund0.07%
VANGUARD BALANCED INDEX FUND0.05%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.04%
Victory Extended Market Index Fund0.01%

OakChart. GUTS. Cached 15 minutes.